Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index, with the former declining by 0.37% to close at 3559.95 points and the latter dropping by 1.07% to 24507.81 points [1] - Fudan Zhangjiang's A/H share premium reached 182.7%, ranking fourth among A/H shares, with A-shares closing at 10.83 yuan (up 0.19%) and H-shares at 4.17 HKD (up 1.96%) [1] - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] Group 2 - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 二零二五年七月三十日 趙大君 主席 - 1 - 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 董事會會議通告 上海復旦張江生物醫藥股份有限公司（「本公司」）之董事會（「董事會」）謹 此公佈，將於二零二五年八月十二日（星期二）舉行董事會會議，以審議及通過 （其中包括）本公司及其附屬公司截至二零二五年六月三十日止六個月之未經審核 中期業績及考慮宣派中期股息（如有）。 承董事會命 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） * 僅供識別 - 2 - ...

金融界消息 截至2025年7月29日收盘，复旦张江（688505）报收于10.75元，上涨2.97%，换手率 3.63%，成交量25.78万手，成交金额2.74亿元。 资金流向方面，今日主力资金净流入2811.73万元，占比成交额10.24%。其中，超大单净流入1676.64万 元、占成交额6.11%，大单净流入1135.08万元、占成交额4.14%，中单净流出流出435.29万元、占成交 额1.59%，小单净流出2376.43万元、占成交额8.66%。 天眼查商业履历信息显示，上海复旦张江生物医药股份有限公司，成立于1996年，位于上海市，是一家 以从事专业技术服务业为主的企业。企业注册资本10365.721万人民币，实缴资本10365.721万人民币。 公司法定代表人为赵大君。 通过天眼查大数据分析，上海复旦张江生物医药股份有限公司共对外投资了8家企业，参与招投标项目 270次，知识产权方面有商标信息44条，专利信息184条，此外企业还拥有行政许可78个。 来源：金融界 复旦张江最新一期业绩显示，截至2025一季报，公司营业总收入1.80亿元、同比增长21.85%，归属净利 润266.51万元，同比增长1 ...

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index on July 29, with the former rising by 0.33% to close at 3609.71 points and the latter falling by 0.15% to close at 25524.45 points [1] - Fudan Zhangjiang's A/H share premium reached 171.57%, ranking fourth among A/H shares, with A shares closing at 10.75 yuan (up 2.97%) and H shares at 4.33 HKD (up 2.61%) [1] - Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] Group 2 - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Over the years, the company has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and the "Major New Drug Creation" science and technology major special project [1]

Group 1 - The major shareholders of Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. are Yang Zongmeng and Wang Haibo, holding 7.18% and 5.41% of the total shares respectively before the reduction plan [1][2] - Yang Zongmeng planned to reduce his holdings by up to 4,270,800 shares, which is 0.41% of the total share capital, due to personal financial needs [1][2] - The reduction plan was disclosed on June 23, 2025, and the actual reduction took place from July 14 to July 16, 2025 [2][3] Group 2 - Yang Zongmeng reduced his holdings by 10,365,721 shares, representing 1.00% of the total share capital, with a total amount of approximately 92.79 million yuan [2][3] - Wang Haibo reduced his holdings by 4,270,722 shares, which is 0.41% of the total share capital, with a total amount of approximately 38.59 million yuan [3] - After the reductions, Yang Zongmeng's remaining shares are 64,009,773, which is 6.18% of the total share capital, while Wang Haibo's remaining shares are 51,828,605, which is 5.00% [3]

关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本 的 7.18%；王海波先生持有公司股份 56,099,327 股，占公司总股本的 5.41%。上 述股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股 份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-024 上海复旦张江生物医药股份有限公司 集中竞价减持计划的实施结果情况 1、2025 年 6 月 23 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-018）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365 ...

Summary of Key Points Core Viewpoint - Fudan Zhangjiang announced that shareholders Yang Zongmeng and Wang Haibo will reduce their holdings in the company through centralized bidding transactions, impacting the total shareholding structure of the company [1] Shareholder Reduction Details - Yang Zongmeng will reduce his holdings by 10.3657 million shares, which accounts for 1.00% of the company's total share capital, between July 14 and July 16, 2025 [1] - Wang Haibo will reduce his holdings by 4.2707 million shares, representing 0.41% of the company's total share capital, between July 14 and July 15, 2025, and has decided to terminate his reduction plan early [1] Post-Reduction Shareholding - After the reduction, Yang Zongmeng will hold 64.0098 million shares, which is 6.18% of the total shares [1] - After the reduction, Wang Haibo will hold 51.8286 million shares, which is 5.00% of the total shares [1]

Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceutical Group [2] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [2] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new products expected to be launched in the future [2] - The company has been recognized as a "High-tech Enterprise" in Shanghai since 1998 and has been involved in several national key technology projects [2] - Fudan Zhangjiang is listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, making it one of the few companies with A+H share listings [2] Financial Performance - As of March 31, 2025, Fudan Zhangjiang reported total revenue of 180 million yuan, a year-on-year increase of 21.85% [1] - The net profit attributable to shareholders was 2.6651 million yuan, reflecting a year-on-year growth of 13.53% [1] - The company's gross margin stood at 91.08%, with a debt-to-asset ratio of 8.82% [1] Stock Performance - As of July 17, the stock price of Fudan Zhangjiang was 4.4 HKD per share, marking a 14.29% increase with a trading volume of 373 million shares and a turnover of 1.744 billion HKD [1] - Over the past month, the stock has gained 14.31%, and year-to-date, it has increased by 57.99%, outperforming the Hang Seng Index, which rose by 22.22% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.45 times, with a median of 6.93 times [1] - Fudan Zhangjiang's P/E ratio is significantly higher at 92.37 times, ranking 73rd in the industry [1] - Comparatively, other companies in the sector have lower P/E ratios, such as Qianjing Pharmaceutical at 0.9 times and King’s Ray Biotechnology at 1.46 times [1]

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Market Overview - The A-share market opened slightly lower on July 17 but then experienced a rebound, with all three major indices showing positive performance, particularly the ChiNext index which rose nearly 1% [2] - The total market capitalization reached 14.20 trillion CNY, with a trading volume of 7698.06 million hands and a turnover rate of 1.46% [3] Pharmaceutical Sector - The pharmaceutical sector saw a significant surge, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical and Chengdu Xian Dao, both reaching a 20% increase [4][5] - Notable stocks in the pharmaceutical sector included: - Chengdu Xian Dao: 21.46 CNY, up 20.02% - Weikang Pharmaceutical: 20.71 CNY, up 19.99% - Other stocks like Lifespring Pharmaceutical and Zhejiang Zhenyuan also saw increases of around 10% [5][6] - The Hong Kong pharmaceutical and biotechnology sector also experienced notable gains, with companies like Fudan Zhangjiang and Kanyin Biotech showing significant price increases [6] Robotics Sector - The humanoid robot concept stocks remained active, with Nanjing Julong hitting the daily limit up of 20%, and other companies like Dongshan Precision and Taijing Technology also seeing substantial gains [7][8] - On July 17, the stock of Aowei New Materials achieved a 20% limit up, marking its seventh consecutive trading day of gains, with a closing price of 27.89 CNY [10][11] Policy Impact - The National Healthcare Security Administration recently announced the initiation of the 11th batch of centralized drug procurement, which will include 55 drug varieties, focusing on mature "old drugs" while excluding innovative drugs from the procurement list [6]